Shao-Wu Jing1, Jian-Jun Qin2, Qing Liu1, Chang Zhai1, Ya-Jing Wu1, Yun-Jie Cheng1, Brian G Czito3, Jun Wang1. 1. Department of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, PR China. 2. Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, PR China. 3. Department of Radiation Oncology, Duke University, Durham, NC 27708, USA.
Abstract
Aim: To compare the clinical efficacy of neoadjuvant chemoradiotherapy (nCRT) and neoadjuvant chemotherapy (nCT) for esophageal cancer. Methods: Randomized controlled trials reporting on the comparison of nCRT and nCT for esophageal cancer were identified. Results: Three eligible randomized controlled trials were identified and included with a total of 375 patients (189 nCRT, 186 nCT). Outcomes showed that compared with nCT group, R0 resection and pathologic complete response (pCR) rates were significantly increased in nCRT group. However, no significant difference was seen in 3- and 5-year progression-free survival or 3- and 5-year overall survival. Conclusion: The addition of radiotherapy to neoadjuvant chemotherapy results in higher R0 resection rate and pCR rate, without significantly impacting survival.
Aim: To compare the clinical efficacy of neoadjuvant chemoradiotherapy (nCRT) and neoadjuvant chemotherapy (nCT) for esophageal cancer. Methods: Randomized controlled trials reporting on the comparison of nCRT and nCT for esophageal cancer were identified. Results: Three eligible randomized controlled trials were identified and included with a total of 375 patients (189 nCRT, 186 nCT). Outcomes showed that compared with nCT group, R0 resection and pathologic complete response (pCR) rates were significantly increased in nCRT group. However, no significant difference was seen in 3- and 5-year progression-free survival or 3- and 5-year overall survival. Conclusion: The addition of radiotherapy to neoadjuvant chemotherapy results in higher R0 resection rate and pCR rate, without significantly impacting survival.
Authors: R Mercieca-Bebber; E H Barnes; K Wilson; Z Samoon; E Walpole; T Mai; S Ackland; M Burge; G Dickie; D Watson; J Leung; T Wang; R Bohmer; D Cameron; J Simes; V Gebski; M Smithers; J Thomas; J Zalcberg; A P Barbour Journal: BMC Cancer Date: 2022-03-15 Impact factor: 4.430